drugset / Trial / NCT02251795

Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects

NCT02251795

Phase 1 Completed 52 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to determine the effect of steady-state plasma concentration of Tipranavir/ritonavir (TPV/r) on platelet aggregation in healthy subjects and investigate the effect of TPV/r at steady state plasma concentrations on other platelet functions and biomarkers of coagulation and fibrinolysis.

Timeline

Start
2007-08
Primary completion
2008-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darunavir Small molecule 600 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified 200 mg
Subject Tipranavir Small molecule 500 mg
Background Aspirin Small molecule

Indications

No indication recorded.